Download App

Log in to access Online Inquiry
Company Overview More
Novavax, Inc., a biotechnology company, focuses on the discovery, development, and commercialization of vaccines to prevent serious infectious diseases and address health needs. The company's vaccine candidates include NVX-CoV2373, a coronavirus vaccine candidate that is in two Phase III trials, one Phase IIb trial, and one Phase I/II trial; NanoFlu, a nanoparticle seasonal quadrivalent influenza vaccine candidate that is in Phase 3 clinical trial; and ResVax, a respiratory syncytial virus (RSV) fusion (F) protein nanoparticle vaccine candidate. It is also developing RSV F vaccine that is in Phase II clinical trial for older adults (60 years and older), as well as that is in Phase I clinical trial for pediatrics. It has a collaboration agreement with Takeda Pharmaceutical Company Limited for the development, manufacturing, and commercialization of NVX-CoV2373, a COVID-19 vaccine candidate. Novavax, Inc. was incorporated in 1987 and is headquartered in Gaithersburg, Maryland.
CEO: Erck, Stanley Charles
Market: NASDAQ
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Moomoo > Quotes > NVAX Novavax > Detailed Quotes

NVAX Novavax

58.430+6.320+12.13%
Close 05/19 20:00 ET
55.940-2.49-4.26%
Pre Mkt Price 05/20 07:00 ET
High
60.565
Open
52.910
Turnover
305.69M
Low
52.670
Pre Close
52.110
Volume
5.33M
Market Cap
4.57B
P/E(TTM)
Loss
52wk High
277.800
Shares
78.13M
P/E(Static)
Loss
52wk Low
41.330
Float Cap
4.55B
Bid/Ask %
0.00%
Historical High
331.680
Shs Float
77.91M
Volume Ratio
1.15
Historical Low
3.540
Dividend TTM
--
Div Yield TTM
--
P/B
69.89
Dividend LFY
--
Div Yield LFY
--
Turnover Ratio
6.84%
Amplitude
15.15%
Avg Price
57.360
Lot Size
1
Float Cap
4.55B
Bid/Ask %
0.00%
Historical High
331.680
Shs Float
77.91M
Volume Ratio
1.15
Historical Low
3.540
Dividend TTM
--
P/B
69.89
Dividend LFY
--
Turnover Ratio
6.84%
Amplitude
15.15%
Avg Price
57.360
Lot Size
1
Price Forecast

No Data

News

Comment